New Developments in Open Innovation in the Pharmaceutical Industry
Open Architecture on the Sales Process of Japanese Pharmaceutical Companies
DOI:
https://doi.org/10.51094/jxiv.813Keywords:
open innovation, sales process, Japanese pharmaceutical companies, ROS (return on sales), value acquisitionAbstract
The report derives the hypothesis that open innovation on the sales process could provide the higher profit margin of Japanese pharmaceutical companies. Based on the case analysis of Takeda, Chugai and Shionogi, which represent Japan pharmaceutical industry, the relationship between the rate of openness on the sales process and the return on sales confirmed a positive correlation. The study also found a positive correlation between the openness on the sales process and the closure on the research process.
In the context of changing drug discovery technologies and scale of markets, Japanese pharmaceutical companies are inferior to global mega-pharmaceutical ones in terms of their sales processes on a global scale. Japanese pharmaceutical companies have another strategic option of open innovation on the sales process for improving the efficiency of value acquisition in a globally competitive market.
Conflicts of Interest Disclosure
TAKAHISA YAMAZAKI is belonging as a director, head of oncology business unit head in Amgen K.K. which is one of the biotech pharmaceutical industry since 2019.Downloads *Displays the aggregated results up to the previous day.
References
AnswersNews (2022). 2021nen ni sekai de mottomo ureta kusuri ha? [The world's best-selling medicines in 2021] (in Japanese). Retrieved 2024/03/26 from https://answers.ten-navi.com/pharmanews/23545/
Chesbrough, H. (2003). Open innovation: The new imperative for creating and profiting from technology. Harvard Business School Press.
Chesbroiugh, H. (2006). Open business model: How to thrive in the new Innovative Landscape. Harvard Business School Press.
Chugai Pharmaceutical CO., LTD. (2002). Strategic Alliance with Roche. Retrieved 2024/3/24 from https://www.chugai-pharm.co.jp/english/ir/roche_alliance/index.html.
Enkel, E. et al. (2009). Open R&D and open innovation: exploring the phenomenon. R&D Management 39(4), 311-316.
Gassmann, O. and Enkel, E. (2004). Towards a theory of open innovation: Three core process archetypes. R&D management conference, 1-18.
Ito, K. (2010). Ikyakuhin meka kachinokori no kyososenryaku [Pharmaceutical manufacturer, Compettive strategy for wining]. Nihon Keizaishimbun Shuppansha (in Japanese).
JOIC. and NEDO. (2020). Opun inobeshon Hakusho dai 3 han [White paper of open innovation, the third edition]. New Energy and Industrial Technology Development Organization (in Japanese). https://www.nedo.go.jp/content/100918466.pdf
Kanama, D. and Nishikawa, K. (2017). Autobaundo gata opun inobeshon no sokushin yoin [Driving factors of outbound open innovation]. Soshiki Kagaku [Organizational science], 51(2), 75-89 (In Japanese).
Kikawa, D. (2021). Iyakuhin kenkyu kaihatsu no ecosisutemu [An ecosystem of pharmaceutical R&D]. Chuou Keizaisha (in Japanese).
Lichtenthaler, U. (2005). External Commercialization of Knowledge: Review and Research Agenda. International Journal of Management Review, 7(4), 231-255.
Manabe, S. and Yasumoto, M. (2010). Opun inobeshon no shoso: Bunken sabei [Aspects of open innovation: Literature survey]. Kenkyu Gijyutu Keikaku [The journal of science policy and research management], 25(1), 68-77 (in Japanese).
Motohashi, K. (2009). Nihon no baio inobeshon. Opun inobeshon no shinten to iyakuhin sangyo no
Kadai [Biotechnology innovation in japan: Advancement of open innovation model and its
challenge for pharma industry]. Hakuto Shobo (in Japanese).
Nihon Yakushi Gakkai, (2014). Dai ichi sho: Nihon iyakuhin sangyo gendaishi (1980 – 2010) souron [Chapter 1 A Contemporary History of the Japanese Pharmaceutical Industry(1980–2010)]. Yakushigaku Zasshi [The Japanese Journal for History of Pharmacy], 49(1), 18-38 (in Japanese).
NIID. (2022). HIV/AIDS 2021. Infectious Agents Surveillance Report. 43(10), 221-223 (in Japanese).
Nobeoka, K. (2010). Opun inobeshon no kansei: Kachi zukuri niokeru mondaiten [Pitfall of open innovation: Issues in value creation]. Kenkyu Gijyutu Keikaku [The journal of science policy and research management], 25(1), 8-35 (in Japanese).
Pisano, G. P. (2006). Science business: The promise, the reality, and the future of biotech. Harvard Business School Press.
Reuters (2018). Takeda-yaku syaiya baisyu de goui ikinokori kaketa 7choen no kyogakubaisyu [Takeda agrees to buy Shire in a massive ¥7 trillion deal for its survival]. (in Japanese). Retrieved 2024/03/24 from https://jp.reuters.com/article/idUSKBN1I90KO/.
Shiota, T. (2018). Shionogi no teibunshi souyaku enjin, soshite jisedai souyaku enjin ni mukete [From the small molecule drug discovery engine to the next generation drug discovery platform, challenge in Shionogi & Co., Ltd.]. Medchem News, 28(4), 154-159 (in Japanese).
Takeishi, A. (2012). Opun inobeshon seikou no mekanizumu to kadai [Open innovation: Mechanisms and challenges for success]. Hitotsubashi Bijinesu Rebyu [Hitotsubashi Business Review], 60(2), 16-26 (in Japanese).
UNAIDS. (2023). Fact sheet - Latest global and regional statistics on the status of the AIDS epidemic. July 13. Retrieved 2024/3/24 from https://www.unaids.org/en/resources/documents/2023/UNAIDS_FactSheet.
Yakuji Nippo, (2008). Takeda yakuhin: Bei mireniamusya wo 88oku doru de baisyu [Takeda Acquired Millennium in the US for USD 8.8 billion] (in Japanese). Retrieved 2024/03/24 from https://www.yakuji.co.jp/entry6417.html.
Yakuji Nippo, (2011). Takeda yakuhin: aikomeddo no baisyu kanryo - Sekai uriagedaka 12 i ni
fujyo [Takeda Completion of the acquisition of Nycomed - now ranked 12th in terms of global sales] (in Japanese). Retrieved 2024/03/24 from https://www.yakuji.co.jp/entry24461.html.
Yamauchi, I. et al. (2017). Autobaundo gata opun inobeshon to inobeshon kouka [Outbound open innovation and innovation performance]. Nihon Chishizai Gakkaishi [Journal of intellectual property association of Japan], 14(1), 5-24 (In Japanese).
Yoshinaga, T. (2019). Shionogi ikagaku kenkyusyo no omoide to HIV-1 integuraze sogaizai dorutegurabiru no souyaku heto tsunagatta kisokenkyu [Memories of the Shionogi institute for medical science and basic research leading to drug discovery of the HIV-1 integrase inhibitor Dolutegravir]. The Journal of AIDS Research, 21(2), 67-69 (in Japanese).
Downloads
Posted
Submitted: 2024-07-08 09:19:56 UTC
Published: 2024-07-10 05:25:14 UTC
License
Copyright (c) 2024
Takahisa Yamazaki
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
